A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Latest Information Update: 20 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PIPER
- 09 Sep 2024 Planned End Date changed from 1 Jun 2027 to 1 Dec 2028.
- 09 Sep 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Dec 2025.
- 01 Nov 2022 Status changed from not yet recruiting to recruiting.